secwatch.observer — SEC 8-K summary
======================================

Issuer:     DELCATH SYSTEMS, INC. (DCTH)
CIK:        0000872912
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001628280-24-023065
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Delcath Systems Q1 2024 revenue jumps to $3.1M; raises center activation target to 20 by year-end
--------------------------------------------------------------------------------

- Revenue $3.1M, up from $0.6M YoY, driven by HEPZATO KIT sales of $2.0M and CHEMOSAT of $1.1M.
- Raised $7.0M in private placement; cash and investments total $27.2M at quarter end.
- Appointed Dr. Martha S. Rook as COO; expanded center activation goal to 20 by end of 2024.
- Received permanent J-code (J9248) and pass-through payment for HEPZATO KIT from CMS effective April 1.
- SG&A rose to $8.8M from $4.2M due to commercial launch; R&D decreased to $3.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872912/000162828024023065/0001628280-24-023065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872912/000162828024023065/dcth-20240513.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-023065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer